Vascular endothelium - Gatekeeper of vessel health

Atherosclerosis

Volumn 248, Issue , 2016, Pages 97-109

  Cahill, Paul A ^a   Redmond, Eileen M ^b  

^a DUBLIN CITY UNIVERSITY   (Ireland)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Atherosclerosis; Cardiovascular disease; Clinical therapies; Endothelial dysfunction; Endothelium; Review; Vessel remodeling

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; ENDOTHELIAL DERIVED RELAXING FACTOR; ENDOTHELIN 1; MICRORNA; NITRIC OXIDE; PROSTACYCLIN; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; VASOCONSTRICTOR AGENT; ANTIINFLAMMATORY AGENT; FIBRINOLYTIC AGENT; VASODILATOR AGENT;

ARTERY ENDOTHELIUM; ARTERY PERMEABILITY; ATHEROSCLEROSIS; BLOOD FLOW; BLOOD VESSEL TONE; BLOOD VESSEL WALL; CARDIOVASCULAR DISEASE; CELL GROWTH; CELL MIGRATION; CELL TRANSFORMATION; DISEASE COURSE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL MESENCHYMAL TRANSITION; ENDOTHELIAL PROGENITOR CELL; EXERCISE; GLYCOCALYX; HEMODYNAMICS; HEMOSTASIS; HUMAN; INFLAMMATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; THROMBOCYTE FUNCTION; VASCULAR DISEASE; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE CELL; VASODILATATION; ANIMAL; CHEMISTRY; CORONARY ARTERY DISEASE; CYTOLOGY; MECHANICAL STRESS; MOUSE; PATHOPHYSIOLOGY; PERMEABILITY; PHYSIOLOGY; STEM CELL; VASCULAR SMOOTH MUSCLE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; ENDOTHELIUM, VASCULAR; EXERCISE; FIBRINOLYTIC AGENTS; GLYCOCALYX; HEMODYNAMICS; HUMANS; INFLAMMATION; MICE; MUSCLE, SMOOTH, VASCULAR; PERMEABILITY; RISK FACTORS; STEM CELLS; STRESS, MECHANICAL; VASOCONSTRICTOR AGENTS; VASODILATOR AGENTS;

EID: 84960876092     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2016.03.007     Document Type: Review

References (233)

1. Ross R. Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 1999, 340:115-126.
2. Mestas J., Ley K. Monocyte-endothelial cell interactions in the development of atherosclerosis. Trends Cardiovasc. Med. 2008, 18:228-232.
3. Libby P., Ridker P.M., Hansson G.K. Progress and challenges in translating the biology of atherosclerosis. Nature 2011, 473:317-325.
4. Blasi C. The autoimmune origin of atherosclerosis. Atherosclerosis 2008, 201:17-32.
5. Morel D.W., DiCorleto P.E., Chisolm G.M. Endothelial and smooth muscle cells alter low density lipoprotein in vitro by free radical oxidation. Arteriosclerosis 1984, 4:357-364.
6. Steinbrecher U.P., Parthasarathy S., Leake D.S., et al. Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc. Natl. Acad. Sci. U. S. A. 1984, 81:3883-3887.
7. Cathcart M.K., Morel D.W., Chisolm G.M. Monocytes and neutrophils oxidize low density lipoprotein making it cytotoxic. J. Leukoc. Biol. 1985, 38:341-350.
8. Parthasarathy S., Printz D.J., Boyd D., et al. Macrophage oxidation of low density lipoprotein generates a modified form recognized by the scavenger receptor. Arteriosclerosis 1986, 6:505-510.
9. Mitra S., Goyal T., Mehta J.L. Oxidized LDL, LOX-1 and atherosclerosis. Cardiovasc. Drugs Ther. Int. Soc. Cardiovasc. Pharmacother. 2011, 25:419-429.
10. Ogunrinade O., Kameya G.T., Truskey G.A. Effect of fluid shear stress on the permeability of the arterial endothelium. Ann. Biomed. Eng. 2002, 30:430-446.
11. Michel C.C., Curry F.E. Microvascular permeability. Physiol. Rev. 1999, 79:703-761.
12. Lum H., Malik A.B. Mechanisms of increased endothelial permeability. Can. J. Physiol. Pharmacol. 1996, 74:787-800.
13. Tilton R.G., Chang K.C., LeJeune W.S., et al. Role for nitric oxide in the hyperpermeability and hemodynamic changes induced by intravenous VEGF. Investig. Ophthalmol. Vis. Sci. 1999, 40:689-696.
14. Ashina K., Tsubosaka Y., Kobayashi K., et al. VEGF-induced blood flow increase causes vascular hyper-permeability in vivo. Biochem. Biophy. Res. Commun. 2015, 464:590-595.
15. Wong B.W., Rahmani M., Luo Z., et al. Vascular endothelial growth factor increases human cardiac microvascular endothelial cell permeability to low-density lipoproteins. J. Heart Lung Transpl. 2009, 28:950-957.
16. Bates D.O. Vascular endothelial growth factors and vascular permeability. Cardiovasc. Res. 2010, 87:262-271.
17. Joshi A.D., Dimitropoulou C., Thangjam G., et al. Heat shock protein 90 inhibitors prevent LPS-induced endothelial barrier dysfunction by disrupting RhoA signaling. Am. J. Respir. Cell Mol. Biol. 2014, 50:170-179.
18. Tarbell J.M. Shear stress and the endothelial transport barrier. Cardiovasc. Res. 2010, 87:320-330.
19. LaMack J.A., Himburg H.A., Li X.M., et al. Interaction of wall shear stress magnitude and gradient in the prediction of arterial macromolecular permeability. Ann. Biomed. Eng. 2005, 33:457-464.
20. Rutledge J.C., Curry F.R., Lenz J.F., et al. Low density lipoprotein transport across a microvascular endothelial barrier after permeability is increased. Circ. Res. 1990, 66:486-495.
21. Soulis J.V., Fytanidis D.K., Papaioannou V.C., et al. Wall shear stress on LDL accumulation in human RCAs. Med. Eng. Phys. 2010, 32:867-877.
22. Berk B.C., Min W., Yan C., et al. Atheroprotective mechanisms activated by fluid shear stress in endothelial cells. Drug News Perspect. 2002, 15:133-139.
23. Skalen K., Gustafsson M., Rydberg E.K., et al. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 2002, 417:750-754.
24. Badimon L., Storey R.F., Vilahur G. Update on lipids, inflammation and atherothrombosis. Thromb. Haemost. 2011, 105(Suppl 1):S34-S42.
25. Rozenberg I., Sluka S.H., Rohrer L., et al. Histamine H1 receptor promotes atherosclerotic lesion formation by increasing vascular permeability for low-density lipoproteins. Arterioscler. Thromb. Vasc. Biol. 2010, 30:923-930.
26. Mullick A.E., McDonald J.M., Melkonian G., et al. Reactive carbonyls from tobacco smoke increase arterial endothelial layer injury. Am. J. Physiol. Heart Circ. Physiol. 2002, 283:H591-H597.
27. Kundumani-Sridharan V., Dyukova E., Hansen D.E., et al. 12/15-Lipoxygenase mediates high-fat diet-induced endothelial tight junction disruption and monocyte transmigration: a new role for 15(S)-hydroxyeicosatetraenoic acid in endothelial cell dysfunction. J. Biol. Chem. 2013, 288:15830-15842.
28. Whyte J.J., Laughlin M.H. The effects of acute and chronic exercise on the vasculature. Acta Physiol. Oxf. 2010, 199:441-450.
29. Garcia J.G., Liu F., Verin A.D., et al. Sphingosine 1-phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement. J. Clin. Investig. 2001, 108:689-701.
30. Xiong Y., Hla T. S1P control of endothelial integrity. Curr. Top. Microbiol. Immunol. 2014, 378:85-105.
31. Argraves K.M., Gazzolo P.J., Groh E.M., et al. High density lipoprotein-associated sphingosine 1-phosphate promotes endothelial barrier function. J. Biol. Chem. 2008, 283:25074-25081.
32. Wilkerson B.A., Grass G.D., Wing S.B., et al. Sphingosine 1-phosphate (S1P) carrier-dependent regulation of endothelial barrier: high density lipoprotein (HDL)-S1P prolongs endothelial barrier enhancement as compared with albumin-S1P via effects on levels, trafficking, and signaling of S1P1. J. Biol. Chem. 2012, 287:44645-44653.
33. Pizurki L., Zhou Z., Glynos K., et al. Angiopoietin-1 inhibits endothelial permeability, neutrophil adherence and IL-8 production. Br. J. Pharmacol. 2003, 139:329-336.
34. Langeler E.G., van Hinsbergh V.W. Norepinephrine and iloprost improve barrier function of human endothelial cell monolayers: role of cAMP. Am. J. Physiol. 1991, 260:C1052-C1059.
35. Surapisitchat J., Beavo J.A. Regulation of endothelial barrier function by cyclic nucleotides: the role of phosphodiesterases. Handb. Exp. Pharmacol. 2011, 193-210.
36. Chappell D., Jacob M., Paul O., et al. The glycocalyx of the human umbilical vein endothelial cell: an impressive structure ex vivo but not in culture. Circ. Res. 2009, 104:1313-1317.
37. Alphonsus C.S., Rodseth R.N. The endothelial glycocalyx: a review of the vascular barrier. Anaesthesia 2014, 69:777-784.
38. Rehm M., Bruegger D., Christ F., et al. Shedding of the endothelial glycocalyx in patients undergoing major vascular surgery with global and regional ischemia. Circulation 2007, 116:1896-1906.
39. Beresewicz A., Czarnowska E., Maczewski M. Ischemic preconditioning and superoxide dismutase protect against endothelial dysfunction and endothelium glycocalyx disruption in the postischemic guinea-pig hearts. Mol. Cell. Biochem. 1998, 186:87-97.
40. Mulivor A.W., Lipowsky H.H. Inflammation- and ischemia-induced shedding of venular glycocalyx. Am. J. Physiol. Heart Circ. Physiol. 2004, 286:H1672-H1680.
41. Henry C.B., Duling B.R. TNF-alpha increases entry of macromolecules into luminal endothelial cell glycocalyx. Am. J. Physiol. Heart Circ. Physiol. 2000, 279:H2815-H2823.
42. Becker B.F., Chappell D., Bruegger D., et al. Therapeutic strategies targeting the endothelial glycocalyx: acute deficits, but great potential. Cardiovasc. Res. 2010, 87:300-310.
43. van den Berg B.M., Spaan J.A., Rolf T.M., et al. Atherogenic region and diet diminish glycocalyx dimension and increase intima-to-media ratios at murine carotid artery bifurcation. Am. J. Physiol. Heart Circ. Physiol. 2006, 290:H915-H920.
44. Gouverneur M., Berg B., Nieuwdorp M., et al. Vasculoprotective properties of the endothelial glycocalyx: effects of fluid shear stress. J. Intern. Med. 2006, 259:393-400.
45. Huxley V.H., Williams D.A. Role of a glycocalyx on coronary arteriole permeability to proteins: evidence from enzyme treatments. Am. J. Physiol. Heart Circ. Physiol. 2000, 278:H1177-H1185.
46. Constantinescu A.A., Vink H., Spaan J.A. Endothelial cell glycocalyx modulates immobilization of leukocytes at the endothelial surface. Arterioscler. Thromb. Vasc. Biol. 2003, 23:1541-1547.
47. Mochizuki S., Vink H., Hiramatsu O., et al. Role of hyaluronic acid glycosaminoglycans in shear-induced endothelium-derived nitric oxide release. Am. J. Physiol. Heart Circ. Physiol. 2003, 285:H722-H726.
48. Kelly R., Ruane-O'Hora T., Noble M.I., et al. Differential inhibition by hyperglycaemia of shear stress- but not acetylcholine-mediated dilatation in the iliac artery of the anaesthetized pig. J. Physiol. 2006, 573:133-145.
49. Drake-Holland A.J., Noble M.I. The important new drug target in cardiovascular medicine-the vascular glycocalyx. Cardiovasc. Hematol. Disord. Drug Targets 2009, 9:118-123.
50. Mennander A.A., Shalaby A., Oksala N., et al. Diazoxide may protect endothelial glycocalyx integrity during coronary artery bypass grafting. Scand. Cardiovasc. J. 2012, 46:339-344.
51. Broekhuizen L.N., Lemkes B.A., Mooij H.L., et al. Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus. Diabetologia 2010, 53:2646-2655.
52. Davies P.F. Flow-mediated endothelial mechanotransduction. Physiol. Rev. 1995, 75:519-560.
53. Ando J., Yamamoto K. Effects of shear stress and stretch on endothelial function. Antioxid. Redox Signal 2011, 15:1389-1403.
54. Ohno M., Gibbons G.H., Dzau V.J., et al. Shear stress elevates endothelial cGMP. Role of a potassium channel and G protein coupling. Circulation 1993, 88:193-197.
55. Koslow A.R., Stromberg R.R., Friedman L.I., et al. A flow system for the study of shear forces upon cultured endothelial cells. J. Biomech. Eng. 1986, 108:338-341.
56. Redmond E.M., Cahill P.A., Sitzmann J.V. Perfused transcapillary smooth muscle and endothelial cell co-culture-a novel in vitro model. In Vitro Cell Dev. Biol. Anim. 1995, 31:601-609.
57. Redmond E.M., Cahill P.A., Sitzmann J.V. Flow-mediated regulation of G-protein expression in cocultured vascular smooth muscle and endothelial cells. Arterioscler. Thromb. Vasc. Biol. 1998, 18:75-83.
58. Kanda K., Matsuda T. Behavior of arterial wall cells cultured on periodically stretched substrates. Cell Transplant. 1993, 2:475-484.
59. Morrow D., Cullen J.P., Cahill P.A., et al. Cyclic strain regulates the Notch/CBF-1 signaling pathway in endothelial cells: role in angiogenic activity. Arterioscler. Thromb. Vasc. Biol. 2007, 27:1289-1296.
60. Hsieh H.J., Liu C.A., Huang B., et al. Shear-induced endothelial mechanotransduction: the interplay between reactive oxygen species (ROS) and nitric oxide (NO) and the pathophysiological implications. J. Biomed. Sci. 2014, 21:3.
61. Resnick N., Collins T., Atkinson W., et al. Platelet-derived growth factor B chain promoter contains a cis-acting fluid shear-stress-responsive element. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:4591-4595.
62. Baeyens N., Mulligan-Kehoe M.J., Corti F., et al. Syndecan 4 is required for endothelial alignment in flow and atheroprotective signaling. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:17308-17313.
63. Liu Y., Collins C., Kiosses W.B., et al. A novel pathway spatiotemporally activates Rac1 and redox signaling in response to fluid shear stress. J. Cell Biol. 2013, 201:863-873.
64. Li J., Hou B., Beech D.J. Endothelial Piezo1: life depends on it. Channels Austin 2015, 9:1-2.
65. Ranade S.S., Qiu Z., Woo S.H., et al. Piezo1, a mechanically activated ion channel, is required for vascular development in mice. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:10347-10352.
66. Jung B., Obinata H., Galvani S., et al. Flow-regulated endothelial S1P receptor-1 signaling sustains vascular development. Dev. Cell 2012, 23:600-610.
67. Cullen J.P., Nicholl S.M., Sayeed S., et al. Plasminogen activator inhibitor-1 deficiency enhances flow-induced smooth muscle cell migration. Thromb. Res. 2004, 114:57-65.
68. Gimbrone M.A., Topper J.N., Nagel T., et al. Endothelial dysfunction, hemodynamic forces, and atherogenesis. Ann. N. Y. Acad. Sci. 2000, 902:230-239. discussion 239-240.
69. Pradhan S., Sumpio B. Molecular and biological effects of hemodynamics on vascular cells. Front. Biosci. J. Virtual Libr. 2004, 9:3276-3285.
70. Chiu J.J., Chien S. Effects of disturbed flow on vascular endothelium: pathophysiological basis and clinical perspectives. Physiol. Rev. 2011, 91:327-387.
71. Heo K.S., Fujiwara K., Abe J. Shear stress and atherosclerosis. Mol. Cells 2014, 37:435-440.
72. Stone P.H., Coskun A.U., Kinlay S., et al. Effect of endothelial shear stress on the progression of coronary artery disease, vascular remodeling, and in-stent restenosis in humans: in vivo 6-month follow-up study. Circulation 2003, 108:438-444.
73. Brooks A.R., Lelkes P.I., Rubanyi G.M. Gene expression profiling of human aortic endothelial cells exposed to disturbed flow and steady laminar flow. Physiol. Genom. 2002, 9:27-41.
74. Dunn J., Thabet S., Jo H. Flow-dependent epigenetic DNA methylation in endothelial gene expression and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2015, 35:1562-1569.
75. Jiang Y.Z., Jimenez J.M., Ou K., et al. Hemodynamic disturbed flow induces differential DNA methylation of endothelial Kruppel-Like Factor 4 promoter in vitro and in vivo. Circ. Res. 2014, 115:32-43.
76. Langille B.L., Adamson S.L. Relationship between blood flow direction and endothelial cell orientation at arterial branch sites in rabbits and mice. Circ. Res. 1981, 48:481-488.
77. Akimoto S., Mitsumata M., Sasaguri T., et al. Laminar shear stress inhibits vascular endothelial cell proliferation by inducing cyclin-dependent kinase inhibitor p21(Sdi1/Cip1/Waf1). Circ. Res. 2000, 86:185-190.
78. Davies P.F., Remuzzi A., Gordon E.J., et al. Turbulent fluid shear stress induces vascular endothelial cell turnover in vitro. Proc. Natl. Acad. Sci. U. S. A. 1986, 83:2114-2117.
79. Von Offenberg Sweeney N., Cummins P.M., Cotter E.J., et al. Cyclic strain-mediated regulation of vascular endothelial cell migration and tube formation. Biochem. Biophy. Res. Commun. 2005, 329:573-582.
80. Rubanyi G.M., Romero J.C., Vanhoutte P.M. Flow-induced release of endothelium-derived relaxing factor. Am. J. Physiol. 1986, 250:H1145-H1149.
81. Bhagyalakshmi A., Frangos J.A. Mechanism of shear-induced prostacyclin production in endothelial cells. Biochem. Biophy. Res. Commun. 1989, 158:31-37.
82. Hendrickson R.J., Cappadona C., Yankah E.N., et al. Sustained pulsatile flow regulates endothelial nitric oxide synthase and cyclooxygenase expression in co-cultured vascular endothelial and smooth muscle cells. J. Mol. Cell Cardiol. 1999, 31:619-629.
83. Kuchan M.J., Frangos J.A. Shear stress regulates endothelin-1 release via protein kinase C and cGMP in cultured endothelial cells. Am. J. Physiol. 1993, 264:H150-H156.
84. Malek A.M., Greene A.L., Izumo S. Regulation of endothelin 1 gene by fluid shear stress is transcriptionally mediated and independent of protein kinase C and cAMP. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:5999-6003.
85. Garg U.C., Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J. Clin. Investig. 1989, 83:1774-1777.
86. Alberts G.F., Peifley K.A., Johns A., et al. Constitutive endothelin-1 overexpression promotes smooth muscle cell proliferation via an external autocrine loop. J. Biol. Chem. 1994, 269:10112-10118.
87. Kohno M., Yokokawa K., Yasunari K., et al. Effect of the endothelin family of peptides on human coronary artery smooth-muscle cell migration. J. Cardiovasc. Pharmacol. 1998, 31(Suppl. 1):S84-S89.
88. Ignarro L.J. Endothelium-derived nitric oxide: actions and properties. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 1989, 3:31-36.
89. Moncada S. Prostacyclin and arterial wall biology. Arteriosclerosis 1982, 2:193-207.
90. Takada Y., Shinkai F., Kondo S., et al. Fluid shear stress increases the expression of thrombomodulin by cultured human endothelial cells. Biochem. Biophy. Res. Commun. 1994, 205:1345-1352.
91. Arisaka T., Mitsumata M., Kawasumi M., et al. Effects of shear stress on glycosaminoglycan synthesis in vascular endothelial cells. Ann. N. Y. Acad. Sci. 1995, 748:543-554.
92. Diamond S.L., Eskin S.G., McIntire L.V. Fluid flow stimulates tissue plasminogen activator secretion by cultured human endothelial cells. Science 1989, 243:1483-1485.
93. Owens G.K., Kumar M.S., Wamhoff B.R. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol. Rev. 2004, 84:767-801.
94. Mitsumata M., Fishel R.S., Nerem R.M., et al. Fluid shear stress stimulates platelet-derived growth factor expression in endothelial cells. Am. J. Physiol. 1993, 265:H3-H8.
95. Malek A.M., Gibbons G.H., Dzau V.J., et al. Fluid shear stress differentially modulates expression of genes encoding basic fibroblast growth factor and platelet-derived growth factor B chain in vascular endothelium. J. Clin. Investig. 1993, 92:2013-2021.
96. Ohno M., Cooke J.P., Dzau V.J., et al. Fluid shear stress induces endothelial transforming growth factor beta-1 transcription and production. Modulation by potassium channel blockade. J. Clin. Investig. 1995, 95:1363-1369.
97. Sterpetti A.V., Cucina A., Morena A.R., et al. Shear stress increases the release of interleukin-1 and interleukin-6 by aortic endothelial cells. Surgery 1993, 114:911-914.
98. Merten M., Chow T., Hellums J.D., et al. A new role for P-selectin in shear-induced platelet aggregation. Circulation 2000, 102:2045-2050.
99. Ando J., Tsuboi H., Korenaga R., et al. Shear stress inhibits adhesion of cultured mouse endothelial cells to lymphocytes by downregulating VCAM-1 expression. Am. J. Physiol. 1994, 267:C679-C687.
100. Gerszten R.E., Lim Y.C., Ding H.T., et al. Adhesion of monocytes to vascular cell adhesion molecule-1-transduced human endothelial cells: implications for atherogenesis. Circ. Res. 1998, 82:871-878.
101. Kaneto H., Katakami N., Matsuhisa M., et al. Role of reactive oxygen species in the progression of type 2 diabetes and atherosclerosis. Mediat. Inflamm. 2010, 2010:453892.
102. Victor V.M., Rocha M., Sola E., et al. Oxidative stress, endothelial dysfunction and atherosclerosis. Curr. Pharm. Des. 2009, 15:2988-3002.
103. Birukov K.G. Cyclic stretch, reactive oxygen species, and vascular remodeling. Antioxid. Redox Signal 2009, 11:1651-1667.
104. Chatterjee S., Browning E.A., Hong N., et al. Membrane depolarization is the trigger for PI3K/Akt activation and leads to the generation of ROS. Am. J. Physiol. Heart Circ. Physiol. 2012, 302:H105-H114.
105. Mowbray A.L., Kang D.H., Rhee S.G., et al. Laminar shear stress up-regulates peroxiredoxins (PRX) in endothelial cells: PRX 1 as a mechanosensitive antioxidant. J. Biol. Chem. 2008, 283:1622-1627.
106. Takabe W., Warabi E., Noguchi N. Anti-atherogenic effect of laminar shear stress via Nrf2 activation. Antioxid. Redox Signal 2011, 15:1415-1426.
107. Liu X.M., Peyton K.J., Durante W. Physiological cyclic strain promotes endothelial cell survival via the induction of heme oxygenase-1. Am. J. Physiol. Heart Circ. Physiol. 2013, 304:H1634-H1643.
108. Cummins P.M., von Offenberg Sweeney N., Killeen M.T., et al. Cyclic strain-mediated matrix metalloproteinase regulation within the vascular endothelium: a force to be reckoned with. Am. J. Physiol. Heart Circ. Physiol. 2007, 292:H28-H42.
109. Liu H.B., Zhang J., Xin S.Y., et al. Mechanosensitive properties in the endothelium and their roles in the regulation of endothelial function. J. Cardiovasc. Pharmacol. 2013, 61:461-470.
110. Kou B., Zhang J., Singer D.R. Effects of cyclic strain on endothelial cell apoptosis and tubulogenesis are dependent on ROS production via NAD(P)H subunit p22phox. Microvasc. Res. 2009, 77:125-133.
111. Martin F.A., McLoughlin A., Rochfort K.D., et al. Regulation of thrombomodulin expression and release in human aortic endothelial cells by cyclic strain. PLoS One 2014, 9:e108254.
112. Jiang Y., Kohara K., Hiwada K. Association between risk factors for atherosclerosis and mechanical forces in carotid artery. Stroke J. Cereb. Circ. 2000, 31:2319-2324.
113. Szostak J., Laurant P. The forgotten face of regular physical exercise: a 'natural' anti-atherogenic activity. Clin. Sci. 2011, 121:91-106.
114. Santos-Parker J.R., LaRocca T.J., Seals D.R. Aerobic exercise and other healthy lifestyle factors that influence vascular aging. Adv. Physiol. Educ. 2014, 38:296-307.
115. Sandrock M., Schulze C., Schmitz D., et al. Physical activity throughout life reduces the atherosclerotic wall process in the carotid artery. Br. J. Sports Med. 2008, 42:839-844.
116. Niebauer J., Hambrecht R., Velich T., et al. Attenuated progression of coronary artery disease after 6 years of multifactorial risk intervention: role of physical exercise. Circulation 1997, 96:2534-2541.
117. Schuler G., Hambrecht R., Schlierf G., et al. Regular physical exercise and low-fat diet. Effects on progression of coronary artery disease. Circulation 1992, 86:1-11.
118. Laughlin M.H., Newcomer S.C., Bender S.B. Importance of hemodynamic forces as signals for exercise-induced changes in endothelial cell phenotype. J. Appl. Physiol. 2008, 104:588-600.
119. Ramkhelawon B., Vilar J., Rivas D., et al. Shear stress regulates angiotensin type 1 receptor expression in endothelial cells. Circ. Res. 2009, 105:869-875.
120. Libby P. Inflammation in atherosclerosis. Nature 2002, 420:868-874.
121. Church T.S., Barlow C.E., Earnest C.P., et al. Associations between cardiorespiratory fitness and C-reactive protein in men. Arterioscler. Thromb. Vasc. Biol. 2002, 22:1869-1876.
122. Kondo N., Nomura M., Nakaya Y., et al. Association of inflammatory marker and highly sensitive C-reactive protein with aerobic exercise capacity, maximum oxygen uptake and insulin resistance in healthy middle-aged volunteers. Circ. J. 2005, 69:452-457.
123. Mora S., Cook N., Buring J.E., et al. Physical activity and reduced risk of cardiovascular events: potential mediating mechanisms. Circulation 2007, 116:2110-2118.
124. Gjevestad G.O., Holven K.B., Ulven S.M. Effects of exercise on gene expression of inflammatory markers in human peripheral blood cells: a systematic review. Curr. Cardiovasc. Risk Rep. 2015, 9:34.
125. Palmefors H., DuttaRoy S., Rundqvist B., et al. The effect of physical activity or exercise on key biomarkers in atherosclerosis-a systematic review. Atherosclerosis 2014, 235:150-161.
126. Furchgott R.F., Zawadzki J.V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980, 288:373-376.
127. Ignarro L.J., Byrns R.E., Buga G.M., et al. Endothelium-derived relaxing factor from pulmonary artery and vein possesses pharmacologic and chemical properties identical to those of nitric oxide radical. Circ. Res. 1987, 61:866-879.
128. Furchgott R.F., Vanhoutte P.M. Endothelium-derived relaxing and contracting factors. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 1989, 3:2007-2018.
129. Moncada S., Higgs E.A. Endogenous nitric oxide: physiology, pathology and clinical relevance. Eur. J. Clin. Investig. 1991, 21:361-374.
130. Gkaliagkousi E., Ferro A. Nitric oxide signalling in the regulation of cardiovascular and platelet function. Front. Biosci. J. Virtual Libr. 2011, 16:1873-1897.
131. Sessa W.C., Harrison J.K., Barber C.M., et al. Molecular cloning and expression of a cDNA encoding endothelial cell nitric oxide synthase. J. Biol. Chem. 1992, 267:15274-15276.
132. Govers R., Rabelink T.J. Cellular regulation of endothelial nitric oxide synthase, American journal of physiology. Ren. Physiol. 2001, 280:F193-F206.
133. Schuler G., Adams V., Goto Y. Role of exercise in the prevention of cardiovascular disease: results, mechanisms, and new perspectives. Eur. Heart J. 2013, 34:1790-1799.
134. Yetik-Anacak G., Catravas J.D. Nitric oxide and the endothelium: history and impact on cardiovascular disease. Vasc. Pharmacol. 2006, 45:268-276.
135. de Nigris F., Lerman L.O., Ignarro S.W., et al. Beneficial effects of antioxidants and L-arginine on oxidation-sensitive gene expression and endothelial NO synthase activity at sites of disturbed shear stress. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:1420-1425.
136. Duckles S.P., Miller V.M. Hormonal modulation of endothelial NO production. Pflugers Arch. 2010, 459:841-851.
137. Thakor A.S., Herrera E.A., Seron-Ferre M., et al. Melatonin and vitamin C increase umbilical blood flow via nitric oxide-dependent mechanisms. J. Pineal Res. 2010, 49:399-406.
138. Jantzen F., Konemann S., Wolff B., et al. Isoprenoid depletion by statins antagonizes cytokine-induced down-regulation of endothelial nitric oxide expression and increases NO synthase activity in human umbilical vein endothelial cells. J. Physiol. Pharmacol. Off. J. Pol. Physiol. Soc. 2007, 58:503-514.
139. Malik S., Sharma A.K., Bharti S., et al. In vivo cardioprotection by pitavastatin from ischemic-reperfusion injury through suppression of IKK/NF-kappaB and upregulation of pAkt-e-NOS. J. Cardiovasc. Pharmacol. 2011, 58:199-206.
140. Datar R., Kaesemeyer W.H., Chandra S., et al. Acute activation of eNOS by statins involves scavenger receptor-B1, G protein subunit Gi, phospholipase C and calcium influx. Br. J. Pharmacol. 2010, 160:1765-1772.
141. Taubert D., Roesen R., Lehmann C., et al. Effects of low habitual cocoa intake on blood pressure and bioactive nitric oxide: a randomized controlled trial. JAMA 2007, 298:49-60.
142. Davda R.K., Chandler L.J., Crews F.T., et al. Ethanol enhances the endothelial nitric oxide synthase response to agonists. Hypertension 1993, 21:939-943.
143. Hendrickson R.J., Cahill P.A., Sitzmann J.V., et al. Ethanol enhances basal and flow-stimulated nitric oxide synthase activity in vitro by activating an inhibitory guanine nucleotide binding protein. J. Pharmacol. Exp. Ther. 1999, 289:1293-1300.
144. Venkov C.D., Myers P.R., Tanner M.A., et al. Ethanol increases endothelial nitric oxide production through modulation of nitric oxide synthase expression. Thromb. Haemost. 1999, 81:638-642.
145. Kleinhenz D.J., Sutliff R.L., Polikandriotis J.A., et al. Chronic ethanol ingestion increases aortic endothelial nitric oxide synthase expression and nitric oxide production in the rat. Alcohol. Clin. Exp. Res. 2008, 32:148-154.
146. Mukamal K.J., Conigrave K.M., Mittleman M.A., et al. Roles of drinking pattern and type of alcohol consumed in coronary heart disease in men. N. Engl. J. Med. 2003, 348:109-118.
147. Ronksley P.E., Brien S.E., Turner B.J., et al. Association of alcohol consumption with selected cardiovascular disease outcomes: a systematic review and meta-analysis. BMJ 2011, 342:d671.
148. Cahill P.A., Redmond E.M. Alcohol and cardiovascular disease -modulation of vascular cell function. Nutrients 2012, 4:297-318.
149. Kapil V., Khambata R.S., Robertson A., et al. Dietary nitrate provides sustained blood pressure lowering in hypertensive patients: a randomized, phase 2, double-blind, placebo-controlled study. Hypertension 2015, 65:320-327.
150. Marsch E., Theelen T.L., Janssen B.J., et al. The effect of prolonged dietary nitrate supplementation on atherosclerosis development. Atherosclerosis 2015, 245:212-221.
151. Fukai T., Ushio-Fukai M. Superoxide dismutases: role in redox signaling, vascular function, and diseases. Antioxid. Redox Signal 2011, 15:1583-1606.
152. Yamagishi S., Matsui T. Nitric oxide, a janus-faced therapeutic target for diabetic microangiopathy-Friend or foe?. Pharmacol. Res. 2011, 64:187-194.
153. Okahara K., Sun B., Kambayashi J. Upregulation of prostacyclin synthesis-related gene expression by shear stress in vascular endothelial cells. Arterioscler. Thromb. Vasc. Biol. 1998, 18:1922-1926.
154. Flammer A.J., Luscher T.F. Human endothelial dysfunction: EDRFs. Pflugers Arch. Eur. J. Physiol. 2010, 459:1005-1013.
155. Moncada S., Gryglewski R., Bunting S., et al. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976, 263:663-665.
156. Narumiya S., Sugimoto Y., Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol. Rev. 1999, 79:1193-1226.
157. Smyth E.M., Grosser T., Wang M., et al. Prostanoids in health and disease. J. Lipid Res. 2009, 50(Suppl. S423-428).
158. Szerafin T., Erdei N., Fulop T., et al. Increased cyclooxygenase-2 expression and prostaglandin-mediated dilation in coronary arterioles of patients with diabetes mellitus. Circ. Res. 2006, 99:e12-17.
159. Radomski M.W., Palmer R.M., Moncada S. Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets. Br. J. Pharmacol. 1987, 92:181-187.
160. Kawabe J., Ushikubi F., Hasebe N. Prostacyclin in vascular diseases. - Recent insights and future perspectives. Circ. J. Off. J. Jpn. Circ. Soc. 2010, 74:836-843.
161. Shimokawa H., Flavahan N.A., Lorenz R.R., et al. Prostacyclin releases endothelium-derived relaxing factor and potentiates its action in coronary arteries of the pig. Br. J. Pharmacol. 1988, 95:1197-1203.
162. Delpy E., Coste H., Gouville A.C. Effects of cyclic GMP elevation on isoprenaline-induced increase in cyclic AMP and relaxation in rat aortic smooth muscle: role of phosphodiesterase 3. Br. J. Pharmacol. 1996, 119:471-478.
163. Isogaya M., Yamada N., Koike H., et al. Inhibition of restenosis by beraprost sodium (a prostaglandin I2 analogue) in the atherosclerotic rabbit artery after angioplasty. J. Cardiovasc. Pharmacol. 1995, 25:947-952.
164. Numaguchi Y., Naruse K., Harada M., et al. Prostacyclin synthase gene transfer accelerates reendothelialization and inhibits neointimal formation in rat carotid arteries after balloon injury. Arterioscler. Thromb. Vasc. Biol. 1999, 19:727-733.
165. Sugawara A., Kudo M., Saito A., et al. Novel effects of beraprost sodium on vasculatures. Int. Angiol. 2010, 29:28-32.
166. Arehart E., Stitham J., Asselbergs F.W., et al. Acceleration of cardiovascular disease by a dysfunctional prostacyclin receptor mutation: potential implications for cyclooxygenase-2 inhibition. Circ. Res. 2008, 102:986-993.
167. Lim H., Dey S.K. A novel pathway of prostacyclin signaling-hanging out with nuclear receptors. Endocrinology 2002, 143:3207-3210.
168. Edwards G., Dora K.A., Gardener M.J., et al. K+ is an endothelium-derived hyperpolarizing factor in rat arteries. Nature 1998, 396:269-272.
169. Taddei S., Versari D., Cipriano A., et al. Identification of a cytochrome P450 2C9-derived endothelium-derived hyperpolarizing factor in essential hypertensive patients. J. Am. Coll. Cardiol. 2006, 48:508-515.
170. Faraci F.M., Sobey C.G., Chrissobolis S., et al. Arachidonate dilates basilar artery by lipoxygenase-dependent mechanism and activation of K(+) channels. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2001, 281:R246-R253.
171. Ellis A., Triggle C.R. Endothelium-derived reactive oxygen species: their relationship to endothelium-dependent hyperpolarization and vascular tone. Can. J. Physiol. Pharmacol. 2003, 81:1013-1028.
172. Wei C.M., Hu S., Miller V.M., et al. Vascular actions of C-type natriuretic peptide in isolated porcine coronary arteries and coronary vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 1994, 205:765-771.
173. Griffith T.M., Chaytor A.T., Edwards D.H. The obligatory link: role of gap junctional communication in endothelium-dependent smooth muscle hyperpolarization. Pharmacol. Res. Off. J. Italian Pharmacol. Soc. 2004, 49:551-564.
174. Yanagisawa M., Inoue A., Ishikawa T., et al. Primary structure, synthesis, and biological activity of rat endothelin, an endothelium-derived vasoconstrictor peptide. Proc. Natl. Acad. Sci. U. S. A. 1988, 85:6964-6967.
175. Thorin E., Webb D.J. Endothelium-derived endothelin-1. Pflugers Arch. Eur. J. Physiol. 2010, 459:951-958.
176. Luscher T.F., Yang Z., Tschudi M., et al. Interaction between endothelin-1 and endothelium-derived relaxing factor in human arteries and veins. Circ. Res. 1990, 66:1088-1094.
177. Gilbert P., Tremblay J., Thorin E. Endothelium-derived endothelin-1 reduces cerebral artery sensitivity to nitric oxide by a protein kinase C-independent pathway. Stroke J. Cereb. Circ. 2001, 32:2351-2355.
178. Callera G., Tostes R., Savoia C., et al. Vasoactive peptides in cardiovascular (patho)physiology. Expert Rev. Cardiovasc. Ther. 2007, 5:531-552.
179. Anggrahini D.W., Emoto N., Nakayama K., et al. Vascular endothelial cell-derived endothelin-1 mediates vascular inflammation and neointima formation following blood flow cessation. Cardiovasc. Res. 2009, 82:143-151.
180. Ivey M.E., Osman N., Little P.J. Endothelin-1 signalling in vascular smooth muscle: pathways controlling cellular functions associated with atherosclerosis. Atherosclerosis 2008, 199:237-247.
181. Ihling C., Szombathy T., Bohrmann B., et al. Coexpression of endothelin-converting enzyme-1 and endothelin-1 in different stages of human atherosclerosis. Circulation 2001, 104:864-869.
182. Arai H., Hori S., Aramori I., et al. Cloning and expression of a cDNA encoding an endothelin receptor. Nature 1990, 348:730-732.
183. Sakurai T., Yanagisawa M., Takuwa Y., et al. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 1990, 348:732-735.
184. de Nucci G., Thomas R., D'Orleans-Juste P., et al. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc. Natl. Acad. Sci. U. S. A. 1988, 85:9797-9800.
185. Dhaun N., Pollock D.M., Goddard J., et al. Selective and mixed endothelin receptor antagonism in cardiovascular disease. Trends Pharmacol. Sci. 2007, 28:573-579.
186. Maguire J.J., Davenport A.P. Endothelin@25-new agonists, antagonists, inhibitors and emerging research frontiers: IUPHAR Review 12. Br. J. Pharmacol. 2014, 171:5555-5572.
187. Kowala M.C., Rose P.M., Stein P.D., et al. Selective blockade of the endothelin subtype A receptor decreases early atherosclerosis in hamsters fed cholesterol. Am. J. Pathol. 1995, 146:819-826.
188. Barton M., Haudenschild C.C., d'Uscio L.V., et al. Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:14367-14372.
189. Babaei S., Picard P., Ravandi A., et al. Blockade of endothelin receptors markedly reduces atherosclerosis in LDL receptor deficient mice: role of endothelin in macrophage foam cell formation. Cardiovasc. Res. 2000, 48:158-167.
190. Fukuda D., Sata M. Role of bone marrow renin-angiotensin system in the pathogenesis of atherosclerosis. Pharmacol. Ther. 2008, 118:268-276.
191. Tirapelli C.R., Bonaventura D., Tirapelli L.F., et al. Mechanisms underlying the vascular actions of endothelin 1, angiotensin II and bradykinin in the rat carotid. Pharmacology 2009, 84:111-126.
192. Lemarie C.A., Schiffrin E.L. The angiotensin II type 2 receptor in cardiovascular disease. J. Ren. Angiotensin Aldosterone System JRAAS 2010, 11:19-31.
193. Graninger M., Reiter R., Drucker C., et al. Angiotensin receptor blockade decreases markers of vascular inflammation. J. Cardiovasc. Pharmacol. 2004, 44:335-339.
194. Montecucco F., Pende A., Mach F. The renin-angiotensin system modulates inflammatory processes in atherosclerosis: evidence from basic research and clinical studies. Mediat. Inflamm. 2009, 2009:752406.
195. Jackson S.P. Arterial thrombosis-insidious, unpredictable and deadly. Nat. Med. 2011, 17:1423-1436.
196. Jin R.C., Voetsch B., Loscalzo J. Endogenous mechanisms of inhibition of platelet function. Microcirculation 2005, 12:247-258.
197. Tanaka K.A., Key N.S., Levy J.H. Blood coagulation: hemostasis and thrombin regulation. Anesth. Analg. 2009, 108:1433-1446.
198. Giesen P.L., Fyfe B.S., Fallon J.T., et al. Intimal tissue factor activity is released from the arterial wall after injury. Thromb. Haemost. 2000, 83:622-628.
199. Mackman N. The many faces of tissue factor. J. Thromb. Haemost. JTH 2009, 7(Suppl. 1):136-139.
200. Murata T., Nakashima Y., Yasunaga C., et al. Extracellular and cell-associated localizations of plasminogen activators and plasminogen activator inhibitor-1 in cultured endothelium. Exp. Mol. Pathol. 1991, 55:105-118.
201. Schafer A., Bauersachs J. Endothelial dysfunction, impaired endogenous platelet inhibition and platelet activation in diabetes and atherosclerosis. Curr. Vasc. Pharmacol. 2008, 6:52-60.
202. Ruggeri Z.M. Platelets in atherothrombosis. Nat. Med. 2002, 8:1227-1234.
203. Fujiyama S., Amano K., Uehira K., et al. Bone marrow monocyte lineage cells adhere on injured endothelium in a monocyte chemoattractant protein-1-dependent manner and accelerate reendothelialization as endothelial progenitor cells. Circ. Res. 2003, 93:980-989.
204. Werner N., Priller J., Laufs U., et al. Bone marrow-derived progenitor cells modulate vascular reendothelialization and neointimal formation: effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition. Arterioscler. Thromb. Vasc. Biol. 2002, 22:1567-1572.
205. Asahara T., Murohara T., Sullivan A., et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997, 275:964-967.
206. Williams P.A., Silva E.A. The role of synthetic extracellular matrices in endothelial progenitor cell homing for treatment of vascular disease. Ann. Biomed. Eng. 2015, 43(10):2301-2313.
207. Hou L., Kim J.J., Woo Y.J., et al. Stem cell-based therapies to promote angiogenesis in ischemic cardiovascular disease. Am. J. Physiol. Heart Circ. Physiol. 2015 15, 310(4):H455-H465.
208. Madonna R., De Caterina R. Circulating endothelial progenitor cells: do they live up to their name?. Vasc. Pharmacol. 2015, 67-69:2-5.
209. Hagensen M.K., Shim J., Thim T., et al. Circulating endothelial progenitor cells do not contribute to plaque endothelium in murine atherosclerosis. Circulation 2010, 121:898-905.
210. Ceradini D.J., Kulkarni A.R., Callaghan M.J., et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat. Med. 2004, 10:858-864.
211. Liu P., Zhou B., Gu D., et al. Endothelial progenitor cell therapy in atherosclerosis: a double-edged sword?. Ageing Res. Rev. 2009, 8:83-93.
212. Williamson K., Stringer S.E., Alexander M.Y. Endothelial progenitor cells enter the aging arena. Front. Physiol. 2012, 3:30.
213. Devaraj S., Jialal I. Dysfunctional endothelial progenitor cells in metabolic syndrome. Exp. Diabet. Res. 2012, 2012:585018.
214. Fadini G.P., Agostini C., Avogaro A. Autologous stem cell therapy for peripheral arterial disease meta-analysis and systematic review of the literature. Atherosclerosis 2010, 209:10-17.
215. Tang Z., Wang A., Yuan F., et al. Differentiation of multipotent vascular stem cells contributes to vascular diseases. Nat. Commun. 2012, 3:875.
216. Lao K.H., Zeng L., Xu Q. Endothelial and smooth muscle cell transformation in atherosclerosis. Curr. Opin. Lipidol. 2015, 26(5):449-456.
217. Londin E., Loher P., Telonis A.G., et al. Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- and tissue-specific microRNAs. Proc. Natl. Acad. Sci. U. S. A. 2015, 112:E1106-E1115.
218. Santovito D., Egea V., Weber C. Small but smart: MicroRNAs orchestrate atherosclerosis development and progression. Biochim. Biophys. Acta 2015, S1388-1981(15)00235-8.
219. Schober A., Nazari-Jahantigh M., Weber C. MicroRNA-mediated mechanisms of the cellular stress response in atherosclerosis. Nat. Rev. Cardiol. 2015, 12:361-374.
220. Di Gregoli K., Jenkins N., Salter R., et al. MicroRNA-24 regulates macrophage behavior and retards atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2014, 34:1990-2000.
221. Schober A., Nazari-Jahantigh M., Wei Y., et al. MicroRNA-126-5p promotes endothelial proliferation and limits atherosclerosis by suppressing Dlk1. Nat. Med. 2014, 20:368-376.
222. Harris T.A., Yamakuchi M., Ferlito M., et al. MicroRNA-126 regulates endothelial expression of vascular cell adhesion molecule 1. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:1516-1521.
223. Lovren F., Pan Y., Quan A., et al. MicroRNA-145 targeted therapy reduces atherosclerosis. Circulation 2012, 126:S81-S90.
224. Du F., Yu F., Wang Y., et al. MicroRNA-155 deficiency results in decreased macrophage inflammation and attenuated atherogenesis in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2014, 34:759-767.
225. Meiler S., Baumer Y., Toulmin E., et al. MicroRNA 302a is a novel modulator of cholesterol homeostasis and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2015, 35:323-331.
226. Creemers E.E., Tijsen A.J., Pinto Y.M. Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease?. Circ. Res. 2012, 110:483-495.
227. Kumar S., Kim C.W., Simmons R.D., et al. Role of flow-sensitive microRNAs in endothelial dysfunction and atherosclerosis: mechanosensitive athero-miRs. Arterioscler. Thromb. Vasc. Biol. 2014, 34:2206-2216.
228. Welch-Reardon K.M., Wu N., Hughes C.C. A role for partial endothelial-mesenchymal transitions in angiogenesis?. Arterioscler. Thromb. Vasc. Biol. 2015, 35:303-308.
229. van Meeteren L.A., ten Dijke P. Regulation of endothelial cell plasticity by TGF-beta. Cell Tissue Res. 2012, 347:177-186.
230. Cooley B.C., Nevado J., Mellad J., et al. TGF-beta signaling mediates endothelial-to-mesenchymal transition (EndMT) during vein graft remodeling. Sci. Transl. Med. 2014, 6:227-234.
231. Li Z., Wermuth P.J., Benn B.S., et al. Caveolin-1 deficiency induces spontaneous endothelial-to-mesenchymal transition in murine pulmonary endothelial cells in vitro. Am. J. Pathol. 2013, 182:325-331.
232. Chen P.Y., Qin L., Baeyens N., et al. Endothelial-to-mesenchymal transition drives atherosclerosis progression. J. Clin. Investig. 2015, 2015.
233. Moonen J.R., Lee E.S., Schmidt M., et al. Endothelial-to-mesenchymal transition contributes to fibro-proliferative vascular disease and is modulated by fluid shear stress. Cardiovasc. Res. 2015, 108:377-386.